Repression of cyclic adenosine monophosphate upregulation disarms and expands human regulatory T cells
Journal of immunology. Bd. 188. H. 3. Bethesda, Md.: American Assoc. of Immunologists 2012 S. 1091 - 1097
Erscheinungsjahr: 2012
ISBN/ISSN: 0022-1767
Publikationstyp: Zeitschriftenaufsatz
Sprache: Englisch
Doi/URN: 10.4049/jimmunol.1102045
Geprüft | Bibliothek |
Inhaltszusammenfassung
The main molecular mechanism of human regulatory T cell (Treg)-mediated suppression has not been elucidated. We show in this study that cAMP represents a key regulator of human Treg function. Repression of cAMP production by inhibition of adenylate cyclase activity or augmentation of cAMP degradation through ectopic expression of a cAMP-degrading phosphodiesterase greatly reduces the suppressive activity of human Treg in vitro and in a humanized mouse model in vivo. Notably, cAMP repression a...The main molecular mechanism of human regulatory T cell (Treg)-mediated suppression has not been elucidated. We show in this study that cAMP represents a key regulator of human Treg function. Repression of cAMP production by inhibition of adenylate cyclase activity or augmentation of cAMP degradation through ectopic expression of a cAMP-degrading phosphodiesterase greatly reduces the suppressive activity of human Treg in vitro and in a humanized mouse model in vivo. Notably, cAMP repression additionally abrogates the anergic state of human Treg, accompanied by nuclear translocation of NFATc1 and induction of its short isoform NFATc1/alphaA. Treg expanded under cAMP repression, however, do not convert into effector T cells and regain their anergic state and suppressive activity upon proliferation. Together, these findings reveal the cAMP pathway as an attractive target for clinical intervention with Treg function.» weiterlesen» einklappen
Autoren
Klassifikation
DFG Fachgebiet:
Mikrobiologie, Virologie und Immunologie
DDC Sachgruppe:
Medizin